. Introduction {#s02}
==============

Gastric cancer (GC) is a malignant carcinoma of the digestive tract and has become the third highest cause of carcinoma-associated deaths worldwide^[@b1]^. Although advances in diagnoses and treatment may reduce mortality and morbidity, the 5-year survival rate remains poor^[@b2]^. In 2016, 26,370 patients had GC, and 10,730 patients died from GC in the United States^[@b3]^. Because the carcinogenic mechanism of GC is not fully understood, GC has affected public health and has become a common concern. As with other complex diseases, the development of GC is a complicated, multistep, multifactorial process, with various potential risk factors, including tobacco use, diet, alcohol consumption, *Helicobacter pylori* (*HP*) infection, obesity, and a history of stomach disorder^[@b4]^. In addition, the development of GC may be related to genetic susceptibility factors^[@b5]-[@b8],[@b12]-[@b14]^. Single nucleotide polymorphisms (SNPs), a common type of genetic mutation, may accelerate the development of GC. Genome-wide association studies (GWAS) may be able to identify sequence variations in the human genome, screen SNPs related to human diseases^[@b5]^, and extend our understanding of associations between genetic variations and cancer risk^[@b6]^. To date, two-stage GWAS (discovery and replication) have discovered millions of SNPs and identified relationships between candidate-gene SNPs and disease susceptibility^[@b7],[@b8]^. There are two limitations associated with the study of candidate genes: small sample size and low statistical power. A more precise and true association can be observed *via* a meta-analysis using previously available results^[@b9],[@b10]^. In 2008, Dong et al.^[@b11]^ performed a meta-analysis and reported that six variants were significantly associated with the risk of GC. Subsequently, more GC-related genes or loci have been discovered in research on genetic variants and identified in GWAS. In 2010, Abnet et al.^[@b12]^ identified two identified GC-related loci (3q13.31 and 5p13.1). In 2011, Jin et al.^[@b13]^ found a locus (6p21.1) associated with GC in a GWAS. Later, Hu et al.^[@b14]^ identified a new locus (1q22) associated with GC, and Wang et al.^[@b15]^ found two novel loci (5q14.3 and 8q24.3) associated with GC. Recently, the results of most meta-analyses for same variant have been inconsistent, suggesting the possibility of false positive associations. Although meta-analyses involving large numbers of patients may reflect true associations between genetic variants and GC risk, the credibility and strength of these associations need to be further assessed^[@b16]^.

Therefore, a comprehensive review associated with genetic susceptibility to GC is needed. Our study assesses the credibility and strength of significant associations between candidate-gene SNPs and GC risk and provides comprehensive information for further investigation.

. Methods {#s03}
=========

. Literature search {#s03.01}
-------------------

Web of Science, PubMed, and Medline were searched to identify relevant meta-analyses published on before July 30th, 2018 using the following terms: ("gastric") and ("cancer" or "carcinoma" or "adenocarcinoma" or "tumor" or "malignant" or "malignancy" or "neoplasm" or "neoplasia" or "oncology") and ("genetic" or "gene" or "polymorphism" or "SNP" or "single nucleotide polymorphism" or "genetic variant") and ("meta-analysis"). Additionally, we examined all relevant references to identify potential meta-analyses that could offer relevant data.

. Criteria for selection {#s03.02}
------------------------

We used the following criteria to screen meta-analyses : (i) publications were in English, (ii) cancer type was GC, (iii) patients with GC were pathologically or histologically confirmed, (iv) the sample size was not fewer than 1,000, and (v) the studies were on GC incidence (rather than mortality or survival rate). Meta-analyses of GWAS were obtained from PubMed. We used the following criteria for GWAS-related articles: (i) publications were in English; (ii) cancer type was GC, which includes all GC subtypes; (iii) patients with GC were pathologically or histologically confirmed; (iv) the studies were on GC incidence (rather than mortality or survival rate); and (v) the studies included two phases (discovery and replication).

. Data extraction {#s03.03}
-----------------

Two authors (J.T. and G.L.) worked together to extract all data. Any disagreement was resolved by further discussion. The publication details collected included: first author, publication year, gene name, genetic variant, odds ratio (OR), and 95% confidence intervals (CIs) under the additive model, number of studies, number of subjects (cases and controls), ethnicity of participants, I-square (I^2^), heterogeneity (Q test)^[@b17]^, and publication bias (Egger's test)^[@b18]^. For GWAS, the following inclusion criteria were reported for SNPs: (i) the results contained two stages (discovery and replication), (ii) the OR and 95% CI could be collected, and (iii) the *P* value was less than the cutoff of 5 × 10^--8^. The publication details collected for each eligible qualified SNP included: PubMed identifier (PMID) number, first author, publication year, gene name, genetic variant, ethnicity of participants, number of subjects (cases and controls), minor allele frequency (MAF), OR and 95% CI, and *P*-value.

The eligible studies reported two major ethnicities: Asian and Caucasian. Twenty meta-analyses reported a single ethnicity; however, several others reported "diverse populations" indicative of two or more ethnicities. Some studies grouped their results by ethnicity, providing data on subgroup analyses. If the same genetic variant was reported in more than one study, we selected the most recently published study with the greatest number and most integrated participants. Current gene names were used to identify the different variants. A *P*-value of 0.05 or less was considered significant. Many studies utilized different genetic models; we selected the additive model (**[Supplementary Table S1](#TableS1){ref-type="table"}**) as our unified model to extract data and mitigate selection bias. As we were unable to use certain SNPs (*n* = 20) in the additive model, dominant, recessive, and homozygous models were also used where necessary.

###### 

The complete data structure of genetic polymorphism study

  Genotype amount                 
  ----------------- ------ ------ ------
  Case group        a~n~   b~n~   c~n~
  Control group     d~n~   e~n~   f~n~

. Evaluation of cumulative evidence {#s03.04}
-----------------------------------

We employed the Venice criteria to assess the epidemiological credibility of significant associations identified by the meta-analyses^[@b25]^. Credibility was rated as strong, moderate, or weak (grade A, B, or C, respectively) according to three factors: amount of evidence, replication of association, and protection from bias. Evidence was evaluated by summing the number of alleles or genotypes among cases and controls and divided into three groups: greater than 1000, 100--1000, and less than 100, representing grades A, B, and C, respectively. Certain test allele numbers or genotype amounts could not be extracted; in these cases, we searched the MAF from the NCBI SNP database (dbSNP) to calculate the amounts. Association replication was calculated using heterogeneity statistics assigning one of three grades: grade A (I^2^ \< 25%), grade B (25% \< I ^2^ \< 50%), or grade C (I ^2^ \> 50%). Bias was evaluated using the *P*-value for publication bias; grade A indicated no observed publication bias (*P* \> 0.05), grade B indicated bias accompanied by a lack of information for identification of evidence, and grade C indicated that bias was statistically evident ( *P* \< 0.05). The magnitude of association was related to protection from bias; a summary OR less than 1.15 was graded as a C for an association, unless several studies had identified that the association was replicated prospectively with an absence of publication bias. Cumulative epidemiological evidence of significant associations was assigned one of three levels: strong (A was assigned to all three grades), weak (C was assigned to any grade), or moderate (all other combinations).

We performed a false positive report probability (FPRP) assay with a prior probability of 0.001 and an FPRP cut-off value of 0.2 to uncover potential false positive results among significant associations, and to evaluate whether these associations should be omitted, as suggested by Wacholder et al.^[@b19]^. Statistical power and FPRP values were calculated by the Excel spreadsheet offered on website (http://jncicancerspectrum.oupjournals.org/jnci/content/vol96/issue6). If the calculated FPRP value was below the prespecified noteworthiness value of 0.2, we would consider the association noteworthy, indicating that the association might be true. FPRP evidence was categorized according to three levels: strong (FPRP \< 0.05), moderate (0.2 ≤ FPRP ≤ 0.05), or weak (FPRP \> 0.2). An FPRP less than 0.05 triggered an upgrading of cumulative evidence from moderate to strong or from weak to moderate. Conversely, an FPRP greater than 0.2 triggered a downgrading of cumulative evidence from strong to moderate or from moderate to weak.

. Results {#s04}
=========

. Characteristics of the articles included in our study {#s04.01}
-------------------------------------------------------

Our search yielded 1,041 articles (**[Figure 1](#Figure1){ref-type="fig"}**). Of these, 308 articles were excluded as duplicates, 457 articles were excluded as irrelevant (not related to genetic variants or GC) after screening the titles and abstracts; the remaining 276 eligible articles were assessed for full-text review. We further excluded 33 non-meta-analyses, 19 non-genetic polymorphisms, 18 mortality or survival studies, 14 studies without an overall meta-analysis, and 28 studies with insufficient data. Twenty-two studies were screened from the reference publication. Subsequently, 186 meta-analyses were eligible for review; these identified 61 variants associated with the risk of GC. In addition, 18 variants (29.5%) were discovered in 2017.

![Flow diagram of search strategy and study selection](cbm-16-2-361-1){#Figure1}

PubMed was used to identify GWAS related to GC etiology, resulting in a total of five GWAS. All 13 SNPs identified were located within eight genes.

. Significant associations in meta-analyses and GWAS {#s04.02}
----------------------------------------------------

Among the main meta-analyses, cumulative epidemiological evidence was graded for 61 significant associations (**[Table 1](#Table1){ref-type="table"}**). We assessed these associations using Venice criteria. With regards to the amount of evidence, 41 SNPs were Grade A, 13 Grade B, and 0 Grade C. Based on replication of association, 19 were Grade A, 13 were Grade B, and 28 were Grade C. Regarding protection from bias, 52 were Grade A, 7 Grade B, and 0 Grade C. Evidence for association with GC risk was thereby considered strong for seven SNPs, moderate for 17 SNPs, and weak for 29 SNPs based on Venice criteria.

###### 

Statistically significant variants from meta-analysis, false-positive report probabilities (FPRP), and cumulative epidemiological evidence

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene\          Cancer\          Comparison   Ethnicity   OR\            Publication bias/\   I^2^(%)   No.\         Sample\         Number of\         Maf         Venice criteria^a^   Venice\    Power\      FPRP values\   Cumulative epidemiological\
  (variant)      type\                                     (95% CI)       heterogeneity                  of studies   size (cases/\   test allele or\                                     grade      OR of 1.5   at prior\      evidence^b^
                 (year)^Ref^                                                                                          control)        genotype\                                                                  probability\   
                                                                                                                                      (calculated\                                                               of 0.001\      
                                                                                                                                      value according\                                                           at power\      
                                                                                                                                      to MAF)                                                                    OR of 1.5      
  -------------- ---------------- ------------ ----------- -------------- -------------------- --------- ------------ --------------- ------------------ ----------- -------------------- ---------- ----------- -------------- -----------------------------
  ALDH2\         GC\              A*vs*G       Asian       1.17\          No/0.325             0         2            2982\           1618               0.2674      AAA                  Strong     0.999       0.976          Moderate
  (rs671）       (2017)^[@b20]^                            (1.01--1.36)                                               (1153/1829)                                                                                               

  APE1\          GC\              G*vs*T       Diverse     1.77\          \>0.05/0.29          19        4            2113\           1779               0.3863      AAA                  Strong     0.084       0.023          Strong
  (rs1760944)    (2017)^[@b21]^                            (1.40--2.24)                                               (802/1311)                                                                                                

                                               Asian       1.41\          Na                   Na        Na           Na              Na                 Na                                                                     
                                                           (1.09--1.83)                                                                                                                                                         

  APEX1\         GC\              Asp*vs*Glu   Diverse     1.42\          0.16/0.016           71        4            2114\           Na\                0.3756^d^   XCA                  Na                                    Na
  (rs1130409)    (2015)^[@b22]^                            (1.09--1.84)                                               (803/1311)      (1588)                                                                                    

  BIRC5\         GC\              Recessive    Diverse     1.75\          0.948/0.053          61.2^c^   4            1147\           293                0.4752      BCA                  Weak       0.269       0.990          Weak
  (rs9904341)    (2013)^[@b23]^                            (1.07--2.86)                                               (583/564)                                                                                                 

  CD95\          GC\              Recessive    Diverse     1.27\          No/0.495             0         8            4563\           Na\                0.1841^d^   XAA                  Na                                    Na
  (rs2234767)    (2013)^[@b24]^                            (1.05--1.53)                                               (Na/Na)         (0--840)                                                                                  

                                               Asian       1.27\          Na                   Na        Na           Na              Na                 Na                                                                     
                                                           (1.05--1.52)                                                                                                                                                         

  COX-2\         GC\              Dominant     Diverse     1.58\          0.05/0.000           85.4      10           7096\           1157               0.0779      ACA                  Weak       0.399       0.984          Weak
  (rs20417)      (2013)^[@b25]^                            (1.06--2.35)                                               (2198/4898)                                                                                               

  COX-2\         GC\              Dominant     Diverse     1.24\          0.690/0.000          68.8      11           7723\           6123               0.516       ACA                  Weak       0.991       0.876          Weak
  (rs689466)     (2017)^[@b26]^                            (1.06--1.45)                                               (2500/5223)                                                                                               

  DNMT1\         GC\              Dominant     Asian       1.36\          0.982/0.720          0         3            2647\           2558               0.8194      AAA                  Strong     0.881       0.191          Strong
  (rs16999593)   (2017)^[@b27]^                            (1.15--1.60)                                               (999/1675)                                                                                                

  DNMT3A\        GC\              Dominant     Asian       1.20\          Na/0.04              69        3            2996\           Na\                0.1142^d^   XCX                  Na                                    Na
  (rs1550117)    (2016)^[@b28]^                            (1.01--1.42)                                               (1104/1892)     (342--684)                                                                                

  EGF\           GC\              G*vs*A       Diverse     1.18\          0.106/0.009          66.61     7            5194\           6524               0.6071      ACA                  Weak       0.988       0.979          Weak
  (rs4444903)    (2015)^[@b29]^                            (1.00--1.39)                                               (1992/3202)                                                                                               

                                               Asian       1.23\          0.106/0.028          61.48     6            4048\           5471               0.6711      ACA                  Weak       0.988       0.948          Weak
                                                           (1.04--1.46)                                               (2494/2977)                                                                                               

                                               Caucasian   0.91\          Na                   Na        Na           Na              Na                 Na                                                                     
                                                           (0.71--1.15)                                                                                                                                                         

  ERCC2\         GC\              Recessive    Asian       2.41\          0.989/0.701          0         5            3246\           143                0.1266      BAA                  Moderate   0.002       0.055          Moderate
  (rs1052559)    (2012)^[@b30]^                            (1.69--3.43)                                               (1267/1979)                                                                                               

  ERCC2\         GC\              Recessive    Diverse     1.48\          0.045/0.272          19.2      9            5144\           416                0.2528      BAC                  Weak       0.537       0.931          Weak
  (rs1799793)    (2012)^[@b30]^                            (1.12--1.97)                                               (1715/3429)                                                                                               

  Continued                                                                                                                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We then evaluated the probability of a true association with GC risk for the nominally significant variants by calculating their FPRP values. Associations with GC risk showed an FPRP value of less than 0.05 for 12 variants (*GSTT1* null/presence, *MDM2* rs2278744, *PPARG* rs1801282, *TLR4* rs4986790, *IL-17F* rs763780, *HOTAIR* rs920778, *IL-17A* rs2275913, *PRKAA1* rs13361707, *PSCA* rs2294008, *MMP1* rs1799750, *ZBTB20* rs9841504, and *GSTM1* null/present), 0.05--0.2 for 27 variants, and greater than 0.2 for the remaining 14 variants. Finally, nine variants on nine genes were rated as demonstrating strong cumulative epidemiological evidence of association with GC risk after combining Venice criteria and FPRP results, including *APE1* (rs1760944), *DNMT1* (rs16999593), *ERCC5* (rs751402), *GSTT1* (null/presence), *MDM2* (rs2278744), *PPARG* (rs1801282), *TLR4* (rs4986790), *IL-17F* (rs763780), and *CASP8* (rs3834129). A moderate association with risk was found for 11 variants, and weak association for 33 variants. Eight variants in our study could not be graded because of significant differences between calculated and true amounts. Calculated amounts of less than 3,000 were not included for assessment in MAFs obtained from the dbSNP.

In five GWAS, 13 variants were significantly associated with GC risk (**[Table 2](#Table2){ref-type="table"}**)^[@b12]-[@b15],[@b76]^. Eight variants were significantly associated with an increased risk of GC. The opposite associations were found in five variants, all of which were regarded as significant following the FPRP assay. Venice criteria were not applicable to GWAS.

###### 

Statistically significant variants from GWAS

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PMID       Gene        Variant      Ethnicity   Year   OR\             MAF^a^         *P*^b^     Sample\         Power OR of 1.5   FPRP values at prior\   References
                                                         (95% CI)                                  size (cases/\                     probability\            
                                                                                                   control)                          of 0.001 at\            
                                                                                                                                     power OR\               
                                                                                                                                     of 1.5                  
  ---------- ----------- ------------ ----------- ------ --------------- -------------- ---------- --------------- ----------------- ----------------------- ------------
  26701879   ASH1L       rs80142782   Asian       2017   0.62\           Na             1.71E-19   15191\          0.120             0.000                   15
                                                         (0.56--0.69)                              (5572/9619)                                               

  26701879   MUC1        rs4072037    Asian       2017   0.74\           Na             6.28E-17   15191\          0.996             0.000                   15
                                                         (0.69--0.79)                              (5572/9619)                                               

  26701879   LOC\        rs7712641    Asian       2017   0.84\           Na             1.21E-11   15191\          1.000             0.000                   15
             105379076                                   (0.80--0.88)                              (5572/9619)                                               

  26701879   PSCA        rs2294008    Asian       2017   1.20\           Na             5.95E-11   15191\          1.000             0.000                   15
                                                         (1.15--1.28)                              (5572/9619)                                               

  26129866   PRKAA1      rs10074991   Asian       2016   0.80\           Na             4.83E-26   20014\          1.000             0.000                   14
                                                         (0.77--0.83)                              (9758/10256)                                              

  23103227   LRFN2       rs2494938    Asian       2012   1.18\           0.26/0.23      4.91E-09   17721\          1.000             0.000                   13
                                                         (1.12--1.25)                              (4332/13399)                                              

  22037551   ZBTB20      rs9841504    Asian       2011   0.76\           0.11/0.15      1.70E-09   10176\          0.998             0.000                   76
                                                         (0.69--0.83)                              (4294/5882)                                               

  22037551   PRKAA1      rs13361707   Asian       2011   1.41\           0.57/0.48      7.60E-29   10176\          0.915             0.000                   76
                                                         (1.32--1.49)                              (4294/5882)                                               

  20729852   PLCE1       rs2274223    Asian       2010   1.31\           0.209/0.259    8.40E-09   5542\           0.999             0.000                   12
                                                         (1.19--1.43)                              (3302/2240)                                               

  20729852   PLCE1       rs3765524    Asian       2010   1.31\           0.207--0.259   5.32E-09   5542\           0.997             0.000                   12
                                                         (1.20--1.44)                              (3302/2240)                                               

  20729852   PLCE1       rs3781264    Asian       2010   1.36\           0.152/0.199    3.76E-09   5542\           0.975             0.000                   12
                                                         (1.23--1.50))                             (3302/2240)                                               

  20729852   PLCE1       rs11187842   Asian       2010   1.34\           0.147/0.190    2.53E-08   5542\           0.981             0.000                   12
                                                         (1.21--1.49)                              (3302/2240)                                               

  20729852   PLCE1       rs753724     Asian       2010   1.34\           0.147/0.190    1.74E-08   5542\           0.981             0.000                   12
                                                         (1.21--1.49)                              (3302/2240)                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

. Non-significant associations in meta-analyses {#s04.03}
-----------------------------------------------

We performed power analyses to determine the stability of associations. Based on our meta-analysis results, 29 variants were not significantly associated with GC risk^[@b24],[@b25],[@b27],[@b32],[@b33],[@b58],[@b63],[@b77]-[@b93]^. Four variants with sample sizes greater than 10,000 were not significantly associated with GC; further investigations into these variants may not be necessary, including *hOGG1* Ser326Cys^[@b85]^, *IL-1B* rs1143627^[@b86]^, *miR-146a* rs2910164^[@b90]^, and *TGF-β1* rs1800469^[@b58]^. Certain variants presented relatively small sample sizes; as such, the evidence for non-association (**[Supplementary Table S2](#TableS2){ref-type="table"}**) was considered unstable.

###### 

Non-significant association in meta-analysis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  PMID        Gene\         Cancer type   Year   Comparison      Ethnicity   OR\              Publication bias/\   I^2^(%)   No.\         Cases/\       Maf
              (variant)                                                      (95% CI)         heterogeneity                  of studies   control       
  ----------- ------------- ------------- ------ --------------- ----------- ---------------- -------------------- --------- ------------ ------------- -----------
  25154002    ACE1\         GC            2015   DD+DI *vs* II   Diverse     1.06\            0.791/0.317          15.1      6            4262\         0.3746
              (rs4646994)                                                    (0.92--1.21)                                                 (1311/2951)   

  27623072    CCND1\        GC            2016   A *vs* G        Diverse     1.07\            \>0.05/\<0.0001      77        9            3986\         0.512
              (rs603965)                                                     (0.88--1.30)                                                 (1813/2173)   

  24978812    CD14\         GC            2014   Dominant        Diverse     0.99\            0.144/0.005          63        12           5304\         0.4991
              (rs2569190)                                                    (0.77--1.26)                                                 (2968/2336)   

  23681795    CD95L\        GC            2013   Dominant        Diverse     1.02\            No/Na                Na        8            4563\         0.4696^a^
              (rs763110)                                                     (0.83--1.25)                                                 (Na/Na)       

  23681795    CD95\         GC            2013   Dominant        Diverse     1.00\            Na/Na                Na        8            3970\         0.4543^a^
              (rs1800682)                                                    (0.87--1.15)                                                 (Na/Na)       

  21570316    CDH1\         GC            2011   Recessive       Diverse     1.27\            Na/Na                Na        3            1962\         0.2466
              (-616 G\>C)                                                    (0.86--1.88)                                                 (565/1397)    

  25599647    CDH1\         GC            2015   AA *vs* CC      Diverse     1.19\            0.323/0.001          55        22           9679\         0.2545
              (rs16260)                                                      (0.89--1.58)                                                 (4218/9679)   

  21570316    CDH1\         GC            2011   Recessive       Diverse     1.00\            Na/Na                Na        5            2280\         0.2667
              (+54 T\>C)                                                     (0.75--1.34）                                                (996/1284)    

  23775011    COX-2\        GC            2013   A *vs* G        Diverse     0.56\            Na/\<0.01            Na        3            3585\         0.0313
              (-587 G\>A)                                                    (0.19--1.70)                                                 (885/2700)    

  24443269    CYP1A1\       GC            2014   Dominant        Diverse     0.950\           0.017/0.163          30.7      10           3460\         0.2237
              (rs4646903)                                                    (0.800--1.128)                                               (923/2537)    

  24443269    CYP1A1\       GC            2014   Dominant        Diverse     0.936\           0.113/0.876          0         8            4773\         0.1577
              (rs1048943)                                                    (0.786--1.114)                                               (1754/3019)   

  27284439    CYP2E1\       GC            2016   C2 *vs* C1      Diverse     1.02\            No/\<0.0001          61.4      26           9237\         0.1529
              (RsaI/PstI)                                                    (0.86--1.19)                                                 (3727/5510)   

  27284439    CYP2E1\       GC            2016   C *vs* D        Diverse     1.05\            No/0.784             0         6            2595\         0.1861
              (DraI)                                                         (0.91--1.20)                                                 (1225/1370)   

  29332452    DNMT3B\       GC            2017   T *vs* C        Asian       1.25\            Na/0.81              0         5            3040\         0.9706
              (rs2424913)                                                    (0.89--1.76)                                                 (1320/1720)   

  28473984    DNMT1\        GC            2017   Dominant        Asian       1.02\            0.505/0.618          0         3            1469\         0.7173
              (rs2228611)                                                    (0.83--1.26)                                                 (652/817)     

  Continued                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

. Inconsistency among meta-analyses {#s04.04}
-----------------------------------

Controversial results were obtained for 23 variants (**[Supplementary Table S3](#TableS3){ref-type="table"}**). Overall, 16 variants were found to be significantly associated with GC, as follows: *BIRC5* rs9904341, *EGF* rs4444903, *ERCC5* rs2296147, *IL-4* rs2243250, *IL-8* 251T/A, *IL-17F* rs763780, *MMP7* rs11568818, *MMP1* rs1799750, *MMP9* -1562C \> T, *TGF-β1* rs1800470, *TNF-α* rs361525, *DNMT3B* rs1569686, *GSTM1* null/active, *IL-10* -592C \> A, *IL-10* 1082G \> A, and *MMP2* rs243865. Seven variants were found to be non-significant: *CDH1* rs16260, *CDH1* +54T \> C, *hOGG1* Ser726Cys, *IL-1B* rs1143627, *miR-146a* rs2910164, *miR-196a2* rs11614913, and *TGF-β1* rs1800469.

###### 

Inconsistency among meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene/\        Gene\           Cancer type   Year   Comparison       Ethnicity   OR\              Publication bias/\   I^2^(%)   No. of studies   Cases/\       Number of test allele or genotype\    Maf
  PMID          (variant)                                                         (95% CI)         heterogeneity                                   control       (calculated value according to MAF)   
  ------------- --------------- ------------- ------ ---------------- ----------- ---------------- -------------------- --------- ---------------- ------------- ------------------------------------- -----------
  BIRC5-31G/C                                                                                                                                                                                          

  　21611748    BIRC5\          GC            2012   CC *vs*. GG      Diverse     2.88\            0.525/Na             Na        3                707\          Na\                                   0.3886^b^
                (rs9904341)                                                       (0.55--15.00)                                                    (363/344）    (0--275)                              

  　23405077    BIRC5\          GC            2013   CC *vs*. GG+GC   Diverse     1.75\            0.948/0.053          Na^a^     4                1147\         293                                   0.4752
                (rs9904341)                                                       (1.07--2.86)                                                     (583/564)                                           

  　24077840    BIRC5\          GC            2014   CC *vs*. GG      Diverse     2.21\            0.317/0.013          72.4      4                1275\         Na\                                   0.3886^b^
                (rs9904341)                                                       (1.06--4.64)                                                     (451/824)     (0--495)                              

  CDH1                                                                                                                                                                                                 

  　21214416    CDH1\           GC            2011   AA+AC *vs*. CC   Diverse     1.03\            0.114/0.005          Na^a^     15               6196\         2909                                  0.2719
                (rs16260)                                                         (0.86--1.22)                                                     (2509/3687)                                         

  　                                                 AA+AC *vs*. CC   Asian       0.84\            0.114/0.185          Na^a^     7                2671\         1049                                  0.2191
                                                                                  (0.72--0.99)                                                     (1220/1451)                                         

  　                                                 AA+AC *vs*. CC   European    1.26\            0.114/0.022          Na^a^     8                3525\         1860                                  0.3061
                                                                                  (0.98--1.61)                                                     (1289/2236)                                         

  　21570316    CDH1\           GC            2011   AA *vs*. AC+CC   Diverse     1.50\            0.54/Na              Na^a^     17               8337\         586                                   0.2582
                (rs16260)                                                         (1.03--2.19)                                                     (3511/4826)                                         

  　21612411    CDH1\           GC            2011   AA *vs*. AC+CC   Diverse     1.16\            0.606/0.004          Na^a^     14               6421\         488                                   0.2732
                (rs16260)                                                         (0.83--1.63)                                                     (3723/2698)                                         

  　24870781    CDH1\           GC            2014   AA+AC *vs*. CC   Diverse     1.11\            No/0.026             48.3      13               6412\         Na\                                   0.2356^b^
                (rs16260)                                                         (0.95--1.30)                                                     (2722/3690)   (1510--3021)                          

  　25599647    CDH1\           GC            2015   AA *vs*. CC      Diverse     1.19\            0.323/0.001          55        22               9679\         672                                   0.2545
                (rs16260)                                                         (0.89--1.58)                                                     (4218/9679)                                         

  CDH1                                                                                                                                                                                                 

  　21570316    CDH1\           GC            2011   CC *vs*. CT+TT   Diverse     1.00\            Na/Na                Na^a^     5                2280\         248                                   0.2667
                (+54 T\>C)                                                        (0.75--1.34）                                                    (996/1284)                                          

  　24870781    CDH1 +54 T\>C   GC            2014   CC+CT *vs*. TT   Diverse     0.57\            No/0.097             57.1      3                1373\         Na\                                   0.1546^b^
                                                                                  (0.44--0.75)                                                     (643/730)     (434--868)                            

  DNMT3B                                                                                                                                                                                               

  　27356727    DNMT3B\         GC            2016   G *vs*. T        Diverse     0.75\            \>0.05/0.00          91        2                1928\         356                                   0.0953
                (rs1569686)                                                       (0.30--1.88)                                                     (706/1222)                                          

  　27789275    DNMT3B\         GC            2016   Dominant         Asian       0.74\            Na/0.000             81        5                3014\         Na\                                   0.2762^b^
                (rs1569686)                                                       (0.61--0.90)                                                     (1225/1789)   (832--1664)                           

  　29332452    DNMT3B\         GC            2017   T *vs*. G        Asian       1.69\            Na/0.48              0         3                1891\         3342                                  0.8614
                (rs1569686)                                                       (1.36--2.10)                                                     (769/1122)                                          

  EGF                                                                                                                                                                                                  

  　20033794    EGF G61A\       GC            2010   A *vs*. G        Asian       0.80\            0.033/0.389          Na^a^     3                2359\         1370                                  0.3104
                (rs4444903)                                                       (0.71--0.92)                                                     (1019/1340)                                         

  　20207214    EGF 61A\>G\     GC            2010   Dominant         Asian       1.40\            0.108/0.86           0         3                2359\         2159                                  0.6896
                (rs4444903)                                                       (1.03--1.90)                                                     (1019/1340)                                         

  　23403233    EGF 61A\>G\     GC            2013   G *vs*. A        Diverse     1.16\            0.476/0.065          58.5      4                3505\         4401                                  0.5936
                (rs4444903)                                                       (0.96--1.39)                                                     (1181/3505)                                         

  　25729328    EGF 61A\>G\     GC            2014   Dominant         Diverse     1.256\           0.738/0.468          0         6                4309\         Na\                                   0.3948^b^
                (rs4444903)                                                       (1.025--1.539)                                                   (1547/2762)   (1701--3402)                          

  　                                                 Dominant         Asian       1.473\           0.738/0.928          0         5                3115\         Na\                                   0.3948^b^
                                                                                  (1.134--1.914)                                                   (1340/1775)   (1230--2460)                          
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. Discussion {#s05}
============

In this study, we collated epidemiological evidence demonstrating significant associations between genetic variants and GC risk. We extracted related useful information from meta-analyses and GWAS to support a comprehensive assessment for further evaluation. Using FPRP tests and Venice criteria, we evaluated the credibility of this cumulative epidemiological evidence of nominally significant associations. Nine variants on nine genes were rated as demonstrating strong evidence of association with GC risk, including *APE1* rs1760944, *DNMT1* rs16999593, *ERCC5* rs751402, *GSTT1* null/presence, *MDM2* rs2278744, *PPARG* rs1801282, *TLR4* rs4986790, *IL-17F* rs763780, and *CASP8* rs3834129. Eleven variants presented moderate evidence of association with GC risk, and 33 variants presented weak evidence.

Apurinic/apyrimidinic endonuclease 1 (*APE1*), located on chromosome 14q11.2, participates in DNA base excision repair and has been associated with human carcinogenesis^[@b94]-[@b96]^. Our analysis provides strong evidence for an association between the G allele of the *APE1* polymorphism and GC risk *via* an additive model, with a 1.77-fold increased risk of GC in a diverse population with a total sample size of 2,113. This variant promotes the development of cancer by impeding DNA repair activity^[@b97]^. In our subgroup analysis, the mutant G allele also increased the risk of GC compared with the wild-type T allele. However, this study was performed exclusively on the Asian population. One reason that concentrated on single (Asian) population could be the small sample size of this meta-analysis, which made subgroup analyses challenging. Therefore, further investigations into this variant are necessary.

*DNMT1*, located on human chromosome 19p13.2, encodes a protein comprising 1,632 amino acids, which may be associated with the development of carcinoma^[@b98]^. Some studies have suggested that DNA methylation contributes to the progression of GC and that over-expression of *DNMT1* may be associated with GC risk. The AKT-NFκB and STAT3 signaling pathways have been implicated in the over-expression of *DNMT1*, which may cause aberrant DNA methylation on tumor suppressor genes, thereby promoting the progression of GC^[@b99],[@b100]^. There was strong evidence for an association between SNP rs16999593 and GC risk in a sample of 2,647 Asians; this polymorphism occurs on the C allele of *DNMT1* (OR = 1.36, 95% CI = 1.15--1.60). This variant results in a histidine to arginine substitution at position 97 (His97Arg) of the translated sequence, which may disrupt the function of *DNMT1*, thus increasing susceptibility to GC. This study sample was limited to Asian populations, and involved a large proportion of Chinese patients. Further studies should investigate this polymorphism in other ethnic groups.

*ERCC5*, also known as *XPG*, is an endonuclease that may prevent carcinogenesis by excising damaged DNA during the DNA repair process^[@b101]^. A polymorphism (rs751402) is found in the promoter region of *ERCC5* and controls its expression and function during transcription in healthy human cells^[@b102]^. The present study showed that this SNP in a dominant model was strongly associated with increased risk of GC; rs751402, which contains a C to T transition, may alter the transcription domain-associated repair capacity of *ERCC5* that could account for its correlation with GC cancer risk in Asians (*n* = 9,814). However, all studies were performed on a single ethnic group (Asian), and we recommend expanding studies on this polymorphism to other populations.

Human *CASP8*, located on chromosome 2q33--q34, participates in cell cycle regulation^[@b103],[@b104]^. This SNP (rs3834129), located in the promoter region of *CASP8*^[@b105]^, leads to reduced expression of this gene. Impaired *CASP8* expression can decrease T lymphocyte-induced cell death^[@b105]^. In the additive model, this SNP was strongly associated with GC, with a 1.14-fold decreased risk of GC in the sample population (*n* = 1,701). The variant inhibits *CASP8* transcription by inactivating the binding site of transcription factor stimulatory protein 1^[@b105]^, potentially altering immune surveillance and decreasing the risk of GC. Although this SNP was only evaluated in case-control studies (not in GWAS), its association with GC risk in the meta-analysis was well established, with an overall schema of AAA. We assigned this SNP a rating of strong evidence because of an FPRP value of less than 0.05. This polymorphism could present a novel target for gene therapy of GC and lead to new drug developments against GC.

Five variants were upgraded from moderate to strong because of an FPRP value less than 0.05, including *GSTT1* null/presence, *MDM2* rs2278744, *PPARG* rs1801282, *TLR4* rs4986790, and *IL-17F* rs763780. Homozygous deletion (null genotype) of *GSTT1* (null/presence) leads to GST enzymatic inactivation and was associated with GC progression in a population of over 20,000^[@b35],[@b106],[@b107]^. Based on these inconsistent results, we assigned strong evidence for the association of this SNP with GC risk, even though this SNP was not evaluated by GWAS. Total samples for the four remaining SNPs were less than 8,000, with 5,400 for *MDM2* rs2278744, 1,418 (546/872) for *PPARG* rs1801282, 5,321 for *TLR4* rs4986790, and 7,346 for *IL-17F* rs763780. According to the results of the FPRP and Venice criteria evaluations, evidence for an association with GC for these four SNPs was not statistically convincing. These results are potentially due to the use of Venice criteria, which accounts for potential bias such as genotyping errors, phenotype misclassifications, and population stratification. Some of the SNPs were difficult to assess using a meta-analysis. It is possible that the results would be more convincing if different weights were assigned to the different categories included in the Venice criteria.

Three SNPs, *ALDH2* rs671, *FASL* rs763110, and *IL-4* rs2243250, were rated as being moderately associated with GC risk; all were downgraded from strong to moderate based on an FPRP greater than 0.2. The FPRP method considers the *P* value, prior probability, and statistical power of the test; as we calculated FPRP at a prior probability of 0.001 and used the statistical power to detect an odds ratio of 1.5 for alleles with an elevated risk in FPRP calculations, some otherwise significant associations may have been excluded. Previous studies using different prior probabilities have classified their results as more noteworthy. Further investigations on these three variants may be necessary to analyze their associations in greater depth.

Seven variants (*HOTAIR* rs920778, *IL-17A* rs2275913, *PRKAA1* rs13361707, *PSCA* rs2294008, *MMP1* rs1799750, *ZBTB20* rs9841504, and *GSTM1* null/present) were rated as being moderately associated with GC risk, after being upgraded from weak to moderate based on their FPRP values (\< 0.05). Among these variants, rs13361707 on*PRKAA1*, rs2294008 on *PSCA*, and rs9841504 on *ZBTB20* were evaluated by meta-analysis and GWAS. A high degree of heterogeneity may explain how all three variants were graded "ACA" overall; these variants were designated as having moderate associations with GC. Two SNPs (rs13361707 and rs2294008) increased GC risk by 1.34- and 1.26-fold in the overall study population, respectively. No statistical data were presented for ethnicity subgroups; which could explain the heterogeneity in the data. We recommend subdividing populations by ethnicity to identify potential differences in the association between these two variants and GC. The variant rs9841504 variant was associated with a 1.26-fold decreased risk of GC in the overall population based on a total sample size of 15,694; this sample included a large number of Asian individuals but relatively few individuals of other ethnicities. We found stronger evidence to support an association for this variant in the Asian population based on the large sample size, but not in the smaller mixed-ethnicity group. While ethnicity may be one factor affecting heterogeneity, other factors such as methodology, GC subtypes, and environmental factors may also as account for variation in the data. Further investigations of this and two further variants (*MMP1* rs1799750 and *HOTAIR* rs920778) are necessary, due to a lack of power in the smaller sample sizes.

Twenty-nine variants were not significantly associated with GC risk, including eight variants on five genes and two miRNAs in a sample of approximately 4,000 patients, at approximately 95% power to detect an OR of 1.15 in an additive model for a variant with MAF of 20%. Most of the MAFs of those eight variants exceeded 0.2, despite sample sizes greater than 4,000. We can therefore conclude, that these eight variants are unlikely to be associated with GC (**[Supplementary Table S4](#TableS4){ref-type="table"}**). It is probable that further investigations evaluating these eight variants will not yield meaningful results with regards to GC.

###### 

The value of power under different model for a variant with different MAF

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene/PMID                   Gene (variant)   Cancer type   Year   Comparison       Ethnicity   OR (95% CI)      No. of studies   The sample size is more than 4000   Maf         Power\   The value of power (%) if the MAF is 0.2   The value of power (%) if the MAF is 0.1
                                                                                                                                                                                   (%)                                                 
  --------------------------- ---------------- ------------- ------ ---------------- ----------- ---------------- ---------------- ----------------------------------- ----------- -------- ------------------------------------------ ------------------------------------------
  ACE1 (insertion/deletion)                                                                                                                                                                                                            

  　25154002                  ACE1\            GC            2015   DD+DI *vs*. II   Diverse     1.06\            6                4262\                               0.3746      85.63    85.68                                      70.67
                              (rs4646994)                                                        (0.92--1.21)                      (1311/2951)                                                                                         

  CCND1\                                                                                                                                                                                                                               
  (G870A)                                                                                                                                                                                                                              

  　27623072                  CCND1\           GC            2016   A *vs*. G        Diverse     1.07\            9                3986\                               0.512       99.28    95.01                                      77.79
                              (rs603965)                                                         (0.88--1.30)                      (1813/2173)                                                                                         

  CD14 159C/T                                                                                                                                                                                                                          

  　24978812                  CD14\            GC            2014   Dominant         Diverse     0.99\            12               5304\                               0.4991      78.82    85.68                                      70.67
                              (rs2569190)                                                        (0.77--1.26)                      (2968/2336)                                                                                         

  CD95                                                                                                                                                                                                                                 

  　23681795                  CD95L\           GC            2013   Dominant         Diverse     1.02\            8                4563\                               0.4696^a^   78.96    85.68                                      70.67
                              (rs763110)                                                         (0.83--1.25)                      (Na/Na)                                                                                             

  CYP1A1                                                                                                                                                                                                                               

  　24443269                  CYP1A1\          GC            2014   Dominant         Diverse     0.936\           8                4773\                               0.1577      82.03    85.68                                      70.67
                              (rs1048943)                                                        (0.786--1.114)                    (1754/3019)                                                                                         

  CYP2E1                                                                                                                                                                                                                               

  　27284439                  CYP2E1\          GC            2016   C2 *vs*. C1      Diverse     1.02\            26               9237\                               0.1529      90.25    95.01                                      77.79
                              (RsaI/PstI)                                                        (0.86--1.19)                      (3727/5510)                                                                                         

  ERCC5                                                                                                                                                                                                                                

  　29072052                  ERCC5\           GC            2017   T *vs*. C        Asian       1.076\           7                7989\                               0.3973      99.16    95.01                                      77.79
                              (rs2094258)                                                        (0.926--1.251)                    (3812/4177)                                                                                         

  ERCC5                                                                                                                                                                                                                                

  　29072052                  ERCC5\           GC            2017   C *vs*. T        Asian       0.95\            6                6477\                               0.3415      98.84    95.01                                      77.79
                              (rs1047768)                                                        (0.880--1.025)                    (3064/3413)                                                                                         

  IL-17A                                                                                                                                                                                                                               

  　26770352                  IL-17A\          GC            2015   T *vs*. C        Asian       1.30\            5                4583\                               0.4144      99.21    95.01                                      77.79
                              (rs3748067)                                                        (0.84--2.03)                      (2160/2423)                                                                                         

  MiR-27a                                                                                                                                                                                                                              

  Continued                                                                                                                                                                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Of the remaining variants, 23 presented inconsistent associations with GC risk, 16 variants were nominally associated with GC risk, and seven variants were conclusively not associated with GC risk. Many studies analyzing the same SNP from this group yielded inconsistent results, due to variation in sample size, selection of association models, and ethnicity. If the same genetic variant was reported in more than one article and the results were not consistent, we selected the most recently published meta-analysis to obtain the highest number or most integrated participants. When selecting association models, the additive one was the model of choice; others were employed only when the additive model was unusable. We extracted information from subgroup analyses based on ethnicity and found that some results for the same variant differed by ethnicity, which may have contributed to inconsistency in the results (**[Supplementary Table S5](#TableS5){ref-type="table"}**). Of note, we found that all GWAS and most of the meta-analyses included in our review were performed in Asian populations. Approximately 40% of all patients with GC worldwide are Asians, with a high proportion found in China. Studies in western populations performed with smaller sample sizes may exist but were not included in our study because of low statistical power. Additional studies on other ethnicities with larger sample groups are strongly recommended for the future.

###### 

Subgroup analysis by ethnicity from inconsistent results of meta-analyses

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  PMID           Gene\            Cancer type   Year   Comparison           Ethnicity   OR\              Publication bias/\   I^2^(%)   No.\         Cases/\
                 (variant)                                                              (95% CI)         heterogeneity                  of studies   control
  -------------- ---------------- ------------- ------ -------------------- ----------- ---------------- -------------------- --------- ------------ -------------
  BIRC5 -31G/C                                                                                                                                       

  　24077840     BIRC5\           GC            2014   CC *vs*. GG          Asian       2.36\            0.392/\<0.001        83.8      2            603\
                 (rs9904341)                                                            (0.28--20.27)                                                (316/287)

  　24077840     BIRC5\           GC            2014   CC *vs*. GG          European    2.33\            Na/Na                Na        1            568\
                 (rs9904341)                                                            (1.22--4.47)                                                 (88/480)

  　24077840     BIRC5\           GC            2014   CC *vs*. GG          Mixed       1.18\            Na/Na                Na        1            104\
                 (rs9904341)                                                            (0.38--3.67)                                                 (47/57)

  CDH1                                                                                                                                               

  　25599647     CDH1\            GC            2015   AA *vs*. CC          Asian       0.92\            0.323/0.008          Na        14           5724\
                 (rs16260)                                                              (0.61--1.38)                                                 (2697/3027)

  　25599647     CDH1\            GC            2015   AA *vs*. CC          Caucasian   1.25\            0.323/0.106          Na        8            3729\
                 (rs16260)                                                              (0.97--1.61)                                                 (1424/2305)

  CDH1                                                                                                                                               

  　21570316     CDH1\            GC            2011   CC *vs*. CT+TT       Asian       0.78\            Na/Na                Na        3            2219\
                 (+54 T\>C)                                                             (0.52--1.16)                                                 (220/226)

  　21570316     CDH1\            GC            2011   CC *vs*. CT+TT       Caucasian   1.35\            Na/Na                Na        2            446\
                 (+54 T\>C)                                                             (0.87--2.08)                                                 (220/226)

  EGF                                                                                                                                                

  　26072068     EGF 61A\>G\      GC            2015   G *vs*. A            Asian       1.23\            0.106/0.028          61.48     6            3976\
                 (rs4444903)                                                            (1.04--1.46)                                                 (1758/2218)

  　26072068     EGF 61A\>G\      GC            2015   G *vs*. A            Caucasian   0.91\            Na                   Na        1            1155\
                 (rs4444903)                                                            (0.71--1.15)                                                 (207/948)

  GSTM1                                                                                                                                              

  　28327825     GSTM1\           GC            2017   null *vs*. present   Asian       0.736\           Na/\<0.0001          Na        50           Na
                 (null/present)                                                         (0.670--0.809)                                               

  　28327825     GSTM1\           GC            2017   null *vs*. present   America     0.866\           Na/\<0.0292          Na        5            Na
                 (null/present)                                                         (0.549--1.364)                                               

  　28327825     GSTM1\           GC            2017   null *vs*. present   Eurasia     0.671\           Na/\<0.6637          Na        3            Na
                 (null/present)                                                         (0.456--0.988)                                               

  　28327825     GSTM1\           GC            2017   null *vs*. present   Europe      1.033\           Na/\<0.0189          Na        12           Na
                 (null/present)                                                         (0.873--1.222)                                               

  hOGG1                                                                                                                                              

  　28415729     hOGG1\           GC            2017   C *vs*. G            Asian       0.98\            No/0.121             38.8      8            6472\
                 (Ser326Cys)                                                            (0.88--1.09)                                                 (2792/3680)

  　28415729     hOGG1\           GC            2017   C *vs*. G            Caucasian   1.08\            No/0.052             61.2      4            2467\
                 (Ser326Cys)                                                            (0.79--1.48)\_                                               (820/1647)

  　28415729     hOGG1\           GC            2017   C *vs*. G            Others      1.07\            No/0.265             24.3      4            1107\
                 (Ser326Cys)                                                            (0.84--1.37)                                                 (412/695)

  IL1B                                                                                                                                               

  　26805397     IL-1B\           GC            2016   Dominant             Asian       0.99\            0.398/0.005          51.2      20           8518\
                 (rs1143627)                                                            (0.85--1.15)                                                 (3694/4824)

  　26805397     IL-1B\           GC            2016   Dominant             Caucasian   1.08\            0.398/0.036          41.8      17           6570\
                 (rs1143627)                                                            (0.90--1.30)                                                 (2414/4156)

  IL-4                                                                                                                                               

  　28656227     IL-4\            GC            2017   C *vs*. T            Asian       1.07\            0.837/0.089          58.6      3            1607\
                 (rs2243250)                                                            (0.88--1.31)                                                 (669/938)

  Continued                                                                                                                                          
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Certain limitations apply to this report. Although we performed a comprehensive literature search, it is possible that some articles may have been missed. Variability in sample size was found among different studies; smaller sizes may have affected the credibility of the data. We evaluated data extracted from a single source, which may have introduced a critical bias. Finally, we only evaluated the susceptibility to, and incidences of association between genetic variants and GC risk; the involvement of genetic polymorphisms as they contribute to tumor progression, metastasis, and drug resistance in GC were not assessed due to a lack of data or information. Despite these limitations, we believe that our study, which provides an updated summary and evaluation of existing literature on the genetic predisposition to GC, will be of value in informing future genetic studies.

This paper evaluated the cumulative epidemiological evidence of significant associations between genetic variants and GC risk by combining Venice criteria and a FPRP assay. Nine SNPs presented strong evidence for an association with GC, of which five variants on five genes were upgraded from moderate to strong evidence based on their FPRP values, and should be further assessed in future studies. If these nine variants are confirmed to be associated with GC risk, they may explain the partial effect of the genetic variant on GC risk. In summary, our study summarizes current literature on the genetic architecture of GC susceptibility, and provides useful data for designing future studies aiming to assess genetic factors for GC risk.
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